Literature DB >> 17904626

Blockade of avidity and focal clustering of beta 2-integrin by cysteinyl leukotriene antagonism attenuates eosinophil adhesion.

Angelo Y Meliton1, Nilda M Munoz, Alan R Leff.   

Abstract

BACKGROUND: Cysteinyl leukotriene (cysLT) antagonism attenuates migration of eosinophils into airways during immune challenge in human subjects and animal models. The intracellular signaling mechanism by which this occurs has not been elucidated.
OBJECTIVE: We sought to determine the relative efficacy and mechanism by which 5-lipoxygenase (5-LO) inhibition and cysLT(1) receptor (cysLT(1)R) antagonism block beta(2)-integrin adhesion in isolated human eosinophils in vitro.
METHODS: Human blood eosinophils were isolated by means of immunomagnetic separation. Upregulation of CD11b expression, active conformation of CD11b, and focal clustering of beta(2)-integrin caused by IL-5, eotaxin-1 or leukotriene (LT) B(4) was assessed by means of flow cytometry and confocal microscopy. The effect and mechanism of cysLT(1)R or 5-LO blockade on these components of beta(2)-integrin adhesion were determined.
RESULTS: Montelukast, a cysLT(1)R antagonist, and AA861, a 5-LO enzyme inhibitor, blocked (1) avidity of beta(2)-integrin, (2) beta(2)-integrin-mediated adhesion to intercellular adhesion molecule 1, and (3) focal clustering of CD11b elicited by LTB(4). However, adhesion caused by either IL-5 or eotaxin-1 was not attenuated for eosinophils pretreated with either montelukast or AA861.
CONCLUSION: Our data demonstrate that (1) LTB(4) causes autocrine upregulation of adhesion through secretion of cysLTs, and (2) blockade of cysLT(1)R blocks the avidity and focal clustering of CD11b/CD18 for eosinophils activated by LTB(4) but not by IL-5 or eotaxin-1. CLINICAL IMPLICATIONS: Unlike cysLT-induced adhesion, adhesion caused by IL-5 or eotaxin-1 is not regulated through the cysLT(1)R, suggesting that cysLTs have specific but limited potential to upregulate eosinophil adhesion.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17904626     DOI: 10.1016/j.jaci.2007.07.038

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  5 in total

1.  Effects of combination therapy with montelukast and carbocysteine in allergen-induced airway hyperresponsiveness and airway inflammation.

Authors:  K Takeda; Y Shiraishi; S Matsubara; N Miyahara; H Matsuda; M Okamoto; A Joetham; E W Gelfand
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 2.  Forkhead box protein A2 and T helper type 2-mediated pulmonary inflammation.

Authors:  Ling Sun; Xiao-Ju Tang; Feng-Ming Luo
Journal:  World J Methodol       Date:  2015-12-26

3.  Foxa2 regulates leukotrienes to inhibit Th2-mediated pulmonary inflammation.

Authors:  Xiaoju Tang; Xiaojing J Liu; Cuijie Tian; Qiaoli Su; Yi Lei; Qingbo Wu; Yangyan He; Jeffrey A Whitsett; Fengming Luo
Journal:  Am J Respir Cell Mol Biol       Date:  2013-12       Impact factor: 6.914

4.  Cysteinyl leukotrienes mediate lymphokine killer activity induced by NKG2D and IL-15 in cytotoxic T cells during celiac disease.

Authors:  Fangming Tang; Benjamin Sally; Kathryn Lesko; Valentina Discepolo; Valerie Abadie; Cezary Ciszewski; Carol Semrad; Stefano Guandalini; Sonia S Kupfer; Bana Jabri
Journal:  J Exp Med       Date:  2015-08-24       Impact factor: 14.307

Review 5.  Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function.

Authors:  A J Theron; H C Steel; G R Tintinger; C M Gravett; R Anderson; C Feldman
Journal:  J Immunol Res       Date:  2014-05-25       Impact factor: 4.818

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.